Patients with FAP Type 2 typically present with symptoms related to peripheral neuropathy, which is damage to the nerves outside the brain and spinal cord. Common symptoms include numbness, tingling, and pain in the hands and feet, muscle weakness, and loss of reflexes. As the disease progresses, patients may experience autonomic dysfunction, affecting bodily functions such as blood pressure regulation, digestion, and bladder control. The onset of symptoms usually occurs in adulthood, often between the ages of 30 and 50.

Diagnosing FAP Type 2 involves a combination of clinical evaluation, family history, and specialized tests. A thorough neurological examination is essential to assess the extent of nerve damage. Genetic testing can confirm the presence of mutations in the TTR gene. Additional tests may include nerve conduction studies to evaluate nerve function, and a biopsy of affected tissue to detect amyloid deposits. Imaging studies, such as MRI, may be used to rule out other conditions.

Treatment for FAP Type 2 focuses on managing symptoms and slowing disease progression. Medications such as pain relievers and drugs to stabilize blood pressure can help alleviate symptoms. Tafamidis and diflunisal are specific drugs that stabilize the TTR protein, reducing amyloid formation. In some cases, liver transplantation may be considered, as the liver produces the majority of TTR protein. Supportive therapies, including physical therapy and occupational therapy, can improve quality of life.

The prognosis for FAP Type 2 varies depending on the severity of symptoms and the effectiveness of treatment. Early diagnosis and intervention can significantly improve outcomes. While the disease is progressive, treatments can help manage symptoms and slow progression, allowing many patients to maintain a good quality of life for several years. However, without treatment, the disease can lead to significant disability and complications.

FAP Type 2 is caused by mutations in the TTR gene, which provides instructions for making transthyretin, a protein that transports thyroid hormone and vitamin A in the blood. Mutations lead to the production of abnormal transthyretin, which forms amyloid deposits in tissues. This genetic disorder is inherited in an autosomal dominant pattern, meaning a single copy of the mutated gene from an affected parent can cause the disease.

FAP Type 2 is a rare condition, with varying prevalence in different populations. It is more common in certain regions, such as Portugal, Sweden, and Japan, where specific TTR mutations are more prevalent. The exact incidence is difficult to determine due to underdiagnosis and misdiagnosis, but it is estimated to affect a small number of individuals worldwide.

The pathophysiology of FAP Type 2 involves the misfolding of transthyretin protein due to genetic mutations. These misfolded proteins aggregate to form amyloid fibrils, which deposit in tissues, particularly around peripheral nerves. The accumulation of amyloid disrupts normal nerve function, leading to the symptoms of peripheral neuropathy and autonomic dysfunction.

Currently, there is no known way to prevent FAP Type 2, as it is a genetic disorder. However, genetic counseling can be beneficial for families with a history of the disease. Identifying carriers of the TTR mutation can help in making informed decisions about family planning and early intervention strategies.

Familial Amyloid Polyneuropathy Type 2 is a rare genetic disorder caused by mutations in the TTR gene, leading to amyloid deposits in peripheral nerves. It presents with symptoms of peripheral neuropathy and autonomic dysfunction. Diagnosis involves genetic testing and clinical evaluation, while treatment focuses on symptom management and slowing disease progression. Early intervention can improve outcomes, although the disease remains progressive.

If you or a family member has been diagnosed with Familial Amyloid Polyneuropathy Type 2, it's important to understand the nature of the disease and its genetic basis. This condition affects the nerves, leading to symptoms like numbness, pain, and muscle weakness. While there is no cure, treatments are available to manage symptoms and improve quality of life. Genetic counseling can provide valuable information for affected families. Regular follow-ups with healthcare providers are essential to monitor the condition and adjust treatments as needed.